BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 24511132)

  • 1. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
    Jha JC; Gray SP; Barit D; Okabe J; El-Osta A; Namikoshi T; Thallas-Bonke V; Wingler K; Szyndralewiez C; Heitz F; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    J Am Soc Nephrol; 2014 Jun; 25(6):1237-54. PubMed ID: 24511132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.
    Gorin Y; Cavaglieri RC; Khazim K; Lee DY; Bruno F; Thakur S; Fanti P; Szyndralewiez C; Barnes JL; Block K; Abboud HE
    Am J Physiol Renal Physiol; 2015 Jun; 308(11):F1276-87. PubMed ID: 25656366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
    Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.
    Gray SP; Jha JC; Kennedy K; van Bommel E; Chew P; Szyndralewiez C; Touyz RM; Schmidt HHHW; Cooper ME; Jandeleit-Dahm KAM
    Diabetologia; 2017 May; 60(5):927-937. PubMed ID: 28160092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.
    Jiang JX; Chen X; Serizawa N; Szyndralewiez C; Page P; Schröder K; Brandes RP; Devaraj S; Török NJ
    Free Radic Biol Med; 2012 Jul; 53(2):289-96. PubMed ID: 22618020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- mice.
    Di Marco E; Gray SP; Chew P; Kennedy K; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Clin Sci (Lond); 2016 Aug; 130(15):1363-74. PubMed ID: 27190136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling.
    Gray SP; Di Marco E; Kennedy K; Chew P; Okabe J; El-Osta A; Calkin AC; Biessen EA; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):295-307. PubMed ID: 26715682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.
    Cha JJ; Min HS; Kim KT; Kim JE; Ghee JY; Kim HW; Lee JE; Han JY; Lee G; Ha HJ; Bae YS; Lee SR; Moon SH; Lee SC; Kim G; Kang YS; Cha DR
    Lab Invest; 2017 Apr; 97(4):419-431. PubMed ID: 28165467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy.
    Sedeek M; Callera G; Montezano A; Gutsol A; Heitz F; Szyndralewiez C; Page P; Kennedy CR; Burns KD; Touyz RM; Hébert RL
    Am J Physiol Renal Physiol; 2010 Dec; 299(6):F1348-58. PubMed ID: 20630933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.
    Aoyama T; Paik YH; Watanabe S; Laleu B; Gaggini F; Fioraso-Cartier L; Molango S; Heitz F; Merlot C; Szyndralewiez C; Page P; Brenner DA
    Hepatology; 2012 Dec; 56(6):2316-27. PubMed ID: 22806357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.
    Lan T; Kisseleva T; Brenner DA
    PLoS One; 2015; 10(7):e0129743. PubMed ID: 26222337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques.
    Xu S; Chamseddine AH; Carrell S; Miller FJ
    Redox Biol; 2014; 2():642-50. PubMed ID: 24936437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
    Sedeek M; Gutsol A; Montezano AC; Burger D; Nguyen Dinh Cat A; Kennedy CR; Burns KD; Cooper ME; Jandeleit-Dahm K; Page P; Szyndralewiez C; Heitz F; Hebert RL; Touyz RM
    Clin Sci (Lond); 2013 Feb; 124(3):191-202. PubMed ID: 22920224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats.
    Dorotea D; Kwon G; Lee JH; Saunders E; Bae YS; Moon SH; Lee SJ; Cha DR; Ha H
    Pharmacology; 2018; 102(3-4):180-189. PubMed ID: 30099457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.
    Li X; Cai W; Lee K; Liu B; Deng Y; Chen Y; Zhang X; He JC; Zhong Y
    Sci Rep; 2017 Nov; 7(1):14603. PubMed ID: 29097815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
    Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
    Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
    Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases.
    Eid AA; Gorin Y; Fagg BM; Maalouf R; Barnes JL; Block K; Abboud HE
    Diabetes; 2009 May; 58(5):1201-11. PubMed ID: 19208908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes.
    Maalouf RM; Eid AA; Gorin YC; Block K; Escobar GP; Bailey S; Abboud HE
    Am J Physiol Cell Physiol; 2012 Feb; 302(3):C597-604. PubMed ID: 22031600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney.
    Gorin Y; Block K; Hernandez J; Bhandari B; Wagner B; Barnes JL; Abboud HE
    J Biol Chem; 2005 Nov; 280(47):39616-26. PubMed ID: 16135519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.